Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Premetastatic Niche ◽

High Risk Prostate Cancer ◽

Risk Prostate Cancer ◽

Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation

The Oncologist ◽

10.1002/onco.13897 ◽

2021 ◽

Author(s):

Akhilesh Sivakumar ◽

Sarah E. Caulfield ◽

Chao Zhang ◽

Subir Goyal ◽

Mehmet A. Bilen ◽

...

Keyword(s):

Retrospective Study ◽

Growth Factor ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Bleeding Risk ◽

Vascular Endothelial ◽

Everolimus zur Behandlung des metastasierten Nierenzellkarzinoms nach Versagen der ersten VEGFr-TKI(Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor)-Therapie: Ergebnisse einer Interimsanalyse einer nichtinterventionellen Studie

Karger Kompass Onkologie ◽

10.1159/000356898 ◽

2014 ◽

Vol 1 (1) ◽

pp. 28-29

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Tyrosine Kinase Inhibitor ◽

Everolimus in Patients with Metastatic Renal Cell Carcinoma Who Progress after Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFR-TKI) Therapy: UK Results from the react Trial on Behalf of the UK React Investigators

Annals of Oncology ◽

10.1016/s0923-7534(20)33390-1 ◽

2012 ◽

Vol 23 ◽

pp. ix271-ix272

Author(s):

S. Chowdhury ◽

J. Larkin

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Renal Cell ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

The Uk ◽

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

European Journal Of Haematology ◽

10.1034/j.1600-0609.2003.01067.x ◽

2003 ◽

Vol 70 (4) ◽

pp. 266-267

Author(s):

K. Anderson

Keyword(s):

Multiple Myeloma ◽

Bone Marrow ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Myeloma Cells ◽

And Migration ◽

Abstract 3681: Vascular endothelial growth factor receptor tyrosine kinase inhibitor inhibited mutated epidermal growth factor receptor-driven tumors ex vivo and in vivo

10.1158/1538-7445.am2011-3681 ◽

2011 ◽

Author(s):

Toshio Kubo ◽

Kadoaki Ohashi ◽

Masahiro Osawa ◽

Hiromasa Takeda ◽

Eiki Ichihara ◽

...

Keyword(s):

Growth Factor ◽

Kinase Inhibitor ◽

Ex Vivo ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Epidermal Growth ◽

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

European Journal of Cancer ◽

10.1016/j.ejca.2011.11.027 ◽

2012 ◽

Vol 48 (3) ◽

pp. 333-339 ◽

Cited By ~ 86

Author(s):

E. Calvo ◽

B. Escudier ◽

R.J. Motzer ◽

S. Oudard ◽

T.E. Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Subgroup Analysis ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Vascular Endothelial ◽

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial

Frontiers in Oncology ◽

10.3389/fonc.2020.00664 ◽

2020 ◽

Vol 10 ◽

Cited By ~ 1

Author(s):

Jianhui Ma ◽

Yan Song ◽

Jianzhong Shou ◽

Yuxian Bai ◽

Hanzhong Li ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase 2 ◽

Phase 2 Trial ◽

Previously Treated ◽

Editorial Comment to Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor

International Journal of Urology ◽

10.1111/iju.12423 ◽

2014 ◽

Vol 21 (7) ◽

pp. 741-741

Author(s):

Yoshihiro Wada

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Kinase Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Previously Treated ◽

Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-015-2725-8 ◽

2015 ◽

Vol 75 (5) ◽

pp. 1025-1035 ◽

Cited By ~ 5

Author(s):

Inkeun Park ◽

Jae-Lyun Lee ◽

Jin-Hee Ahn ◽

Dae-Ho Lee ◽

Kyoo-Hyung Lee ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Treatment Failure ◽

Mtor Inhibitor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

P2-051: Anti-angiogenic Therapy of Human Small-Cell Lung Cancer Cells with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, ZD6474

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283515.14666.26 ◽

2007 ◽

Vol 2 (8) ◽

pp. S510

Author(s):

Takaaki Sasaki ◽

Sachie Tanno ◽

Kiyoko Shibukawa ◽

Eri Toyoshima ◽

Toshiyuki Ogasa ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Vascular Endothelial ◽

Small Cell Lung ◽

Angiogenic Therapy ◽